Table 2.
Proinflammatory cytokine and chemokine expression in kidneys of PepckCreS1pr1wt/wt and PepckCreS1pr1fl/fl mice treated with cisplatin or cisplatin+FTY720
| PepckCreS1pr1wt/wt | PepckCreS1pr1fl/fl | |||
|---|---|---|---|---|
| Cisplatin | Cisplatin+FTY720 | Cisplatin | Cisplatin+FTY720 | |
| CXCL1 | 257.46±151.6a | 62.4±6.8 | 340.1±319.2a | 378.4±83.2 |
| MCP-1 | 188.2±114.1a | 22.7±5.1b | 40.7±25.8a | 87.1±16.3 |
| IL-1β | 21.7±13.1a | 3.7±1.5 | 18.6±11.4a | 175.9±146.6 |
| IL-6 | 503.7±252.1a | 88.3±30.6 | 116.6±67.2a | 192.2±48.8 |
| TNF-α | 96.4±41.0a | 35.5±9.9 | 69.1±38.5a | 51.1±16.5 |
Doses of cisplatin and cisplatin+FTY720 as in Figure 1. mRNA expression (72 hours after cisplatin) relative to glyceraldehyde 3-phosphate dehydrogenase expressed as fold changes compared with vehicle. Values are the mean±SEM. n=3–6 in each group.
a
P<0.05 compared with vehicle.
b
P<0.05 compared with cisplatin.